S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
Log in

NYSE:EBS - Emergent Biosolutions Stock Price, Forecast & News

$55.07
-2.79 (-4.82 %)
(As of 04/1/2020 03:45 PM ET)
Add
Compare
Today's Range
$53.57
Now: $55.07▼
$57.66
50-Day Range
$49.34
MA: $59.04▼
$68.76
52-Week Range
$39.11
Now: $55.07▼
$71.19
Volume28,920 shs
Average Volume675,891 shs
Market Capitalization$2.86 billion
P/E Ratio53.47
Dividend YieldN/A
Beta1.32
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; RSDL (Reactive Skin Decontamination Lotion Kit), a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard for intramuscular self-injection of atropine sulfate and obidoxime chloride. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for treating botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. Further, it provides NuThrax, an anthrax vaccine; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; ADENOVIRUS 4/7, a live attenuated vaccine; rVSV-Lassa, a vaccine for prevention of Lassa fever; rVSV-Marburg, a vaccine for prevention of Marburg hemorrhagic fever; rVSV-Sudan, vaccine for prevention of Sudan hemorrhagic fever; rVSV-QUAD, a vaccine for prevention of hemorrhagic fever; and rVSV-Ebola, a vaccine for prevention of Ebola hemorrhagic fever. Additionally, the company offers FLU-IGIV to treat Influenza A infection in hospitalized patients; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract manufacturing services to third-party customers. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Read More
Emergent Biosolutions logo

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNYSE:EBS
Previous Symbol
CUSIP29089Q10
CIK1367644
Webhttp://www.emergentbiosolutions.com/
Phone240-631-3200

Debt

Debt-to-Equity Ratio0.73
Current Ratio3.17
Quick Ratio2.14

Price-To-Earnings

Trailing P/E Ratio53.47
Forward P/E Ratio16.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.11 billion
Price / Sales2.59
Cash Flow$5.21 per share
Price / Cash Flow10.58
Book Value$21.08 per share
Price / Book2.61

Profitability

EPS (Most Recent Fiscal Year)$2.91
Net Income$54.50 million
Net Margins4.94%
Return on Equity14.19%
Return on Assets6.37%

Miscellaneous

Employees1,834
Outstanding Shares52,000,000
Market Cap$2.86 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

EBS Rates by TradingView

Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions

How has Emergent Biosolutions' stock been impacted by COVID-19 (Coronavirus)?

Emergent Biosolutions' stock was trading at $53.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EBS shares have increased by 3.8% and is now trading at $55.07. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Emergent Biosolutions?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Emergent Biosolutions.

When is Emergent Biosolutions' next earnings date?

Emergent Biosolutions is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Emergent Biosolutions.

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions Inc (NYSE:EBS) issued its earnings results on Thursday, February, 20th. The biopharmaceutical company reported $1.57 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.67 by $0.10. The biopharmaceutical company had revenue of $360.40 million for the quarter, compared to analyst estimates of $357.18 million. Emergent Biosolutions had a return on equity of 14.19% and a net margin of 4.94%. The business's quarterly revenue was up 33.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.75 earnings per share. View Emergent Biosolutions' earnings history.

What guidance has Emergent Biosolutions issued on next quarter's earnings?

Emergent Biosolutions updated its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.175-1.275 billion, compared to the consensus revenue estimate of $1.23 billion.

What price target have analysts set for EBS?

6 analysts have issued 12-month price targets for Emergent Biosolutions' shares. Their forecasts range from $65.00 to $75.00. On average, they anticipate Emergent Biosolutions' share price to reach $70.83 in the next twelve months. This suggests a possible upside of 28.6% from the stock's current price. View analysts' price targets for Emergent Biosolutions.

What are Wall Street analysts saying about Emergent Biosolutions stock?

Here are some recent quotes from research analysts about Emergent Biosolutions stock:
  • 1. Cantor Fitzgerald analysts commented, ". Post 1Q19, we reiterate our Overweight rating and our 12- month price target of $75. EBS continues to be the leader in the biodefense field, and the acquisition of Adapt and PaxVax leverage the company’s historical expertise, while further diversifying revenue away from BioThrax. We continue to believe the company’s business is a lot more durable than the Street is giving it credit for, and we expect Emergent to extend a number of its current contracts beyond current estimates, as well as bring some significant pipeline product to market over time. Emergent does not have the risk of commercial insurance reimbursement or payer pricing pressures on the majority of its portfolio." (5/2/2019)
  • 2. According to Zacks Investment Research, "Emergent BioSolutions' recent acquisitions of PaxVax and Adapt Pharma have expanded the company’s presence in the public health threats market. Its anthrax vaccine, NuThrax’s regulatory application is under review, with a decision expected in the first half of 2019. We are positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the cost structure. Notably, the company derives majority of its revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is a headwind. Moreover, Emergent depends on certain single-source suppliers for key materials and services, which are necessary for manufacturing BioThrax. This, in turn, raises a concern. Shares of the company have underperformed the industry so far this year. Estimates have narrowed ahead of Q1 earnings. Emergent has a mixed record of earnings surprises in the recent quarters." (4/8/2019)

Has Emergent Biosolutions been receiving favorable news coverage?

Media stories about EBS stock have trended very negative recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Emergent Biosolutions earned a news impact score of -3.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutEmergent Biosolutions.

Are investors shorting Emergent Biosolutions?

Emergent Biosolutions saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 2,190,000 shares, a decrease of 10.2% from the February 13th total of 2,440,000 shares. Based on an average trading volume of 338,700 shares, the days-to-cover ratio is presently 6.5 days. Approximately 5.1% of the shares of the company are sold short. View Emergent Biosolutions' Current Options Chain.

Who are some of Emergent Biosolutions' key competitors?

What other stocks do shareholders of Emergent Biosolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include Mercadolibre (MELI), Broadcom (AVGO), Global Payments (GPN), Netflix (NFLX), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC) and NXP Semiconductors (NXPI).

Who are Emergent Biosolutions' key executives?

Emergent Biosolutions' management team includes the following people:
  • Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 61)
  • Mr. Robert G. Kramer Sr., CEO, Pres & Director (Age 62)
  • Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 55)
  • Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 46)
  • Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 48)

What is Emergent Biosolutions' stock symbol?

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

How do I buy shares of Emergent Biosolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Emergent Biosolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $55.07.

How big of a company is Emergent Biosolutions?

Emergent Biosolutions has a market capitalization of $2.86 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $54.50 million in net income (profit) each year or $2.91 on an earnings per share basis. Emergent Biosolutions employs 1,834 workers across the globe. View additional information about Emergent Biosolutions.

What is Emergent Biosolutions' official website?

The official website for Emergent Biosolutions is http://www.emergentbiosolutions.com/.

How can I contact Emergent Biosolutions?

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]


MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  383 (Vote Outperform)
Underperform Votes:  336 (Vote Underperform)
Total Votes:  719
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: FinTech
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel